mercredi 2 novembre 2016

Onco Actu du 2 novembre 2016

1. Biologie

Be your own control: Cancer sequencing differs based on genetic background of reference genome [Colorado Cancer Blogs]

Mark Zuckerberg Is Funding a Facebook for Human Cells [MIT Technology Review]

3.1 Tabac

Why Tobacco Companies Are Spending Millions To Boost A Cigarette Tax [NPR]

India says it is committed to global tobacco-control treaty [Reuters]

3.1.1 Tabac - e-cigs

Safer to Puff, E-Cigarettes Can’t Shake Their Reputation as a Menace [NY Times]

3.2 Prévention - Obésité

To fight childhood obesity, task force recommends screening all kids starting at age 6 [LA Times]

Childhood obesity plan ‘watered down by government’, TV investigation claims [Cancer Research UK]

3.3 Prévention - Vaccins

Anal Cancer Rising Worldwide [ACS]

4. Dépistage, diagnostic et pronostic

Predicting cancer cells’ response to chemotherapy [MIT News]

4.11 Dép., diag. & prono. - Ovaire

Scientists Identify Potential Marker of Resistance to PARP Inhibitors [NCI]

4.2 Dép., diag. & prono. - Génome

Geneticists should offer data to participants [Nature]

Genetic testing fumbles, revealing ‘dark side’ of precision medicine [STAT]

4.9 Dép., diag. & prono. - Sein

Genetic Testing Could Help Identify Breast Cancer Patients at High Risk of Venous Thromboembolism [AACR]

5. Traitements

A look at scientists’ efforts to conquer a deadly brain tumor [Stanford Medicine]

Common genetic disorder linked to increased death rate from cancer drug [Fred Hutch]

5.10 Traitements - Essais

In defense of data sharing, but done in the right way [STAT]

5.12 Immunothérapies

New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma [BMS]

Bristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade [BMS]

5.12.1 Immunothérapies - partenariats

Adaptimmune signs Keytruda/T-cell therapy myeloma tie-up with Merck [FierceBiotech]

5.12.2 Immunothérapies - CAR-T

Insight into exhausted immune cells could open new doors for cancer therapy [STAT]

Immune cells may become ‘exhausted’ during immunotherapy [Cancer Research UK]

5.2 Pharma

Novartis’s blockbuster CDK 4/6 contender LEE011 gets a VIP countdown at the FDA [EndPoints]

Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer [Novartis]

5.2.1 Pharma - Partenariats

Roche licenses out PI3K pathway brain cancer med to Oz biotech [FierceBiotech]

5.2.2 Pharma - Fusions & Acquisitions

Celldex, Aiming For More Cancer Drug Combos, Pays $62.5M For Kolltan [Xconomy]

Post-PhIII implosion, Celldex buys oncology drug developer Kolltan in $235M deal [EndPoints]

5.2.3 Pharma - économie

AstraZeneca R&D leader Pangalos warns of a post-Brexit UK research retreat without reimbursement reform [EndPoints]

Takeda CEO says new myeloma drug Ninlaro will be 'significantly bigger than Velcade' [FiercePharma]

Celgene May Be Ready to Lap Bristol [Bloomberg]

5.3 Traitements - FDA, EMA, NICE...

Merck, Pfizer’s avelumab under review for Merkel cell carcinoma [Pharma Times]

FDA approves clinical trial of Cuban lung cancer vaccine [Pharmafile]

5.4 Traitements - Economie

NICE rejects Merck’s Erbitux [Pharma Times]

5.9 AACR

Researchers Discuss Disruption to DNA Damage Control [AACR]

6. Lutte contre les cancers

Just say death!' Plays teach healthcare workers about end-of-life care [The Guardian]

World Cancer Declaration Progress Report 2016 [UICC]

6.1 Observation

How to understand the rise in the number of cancer cases [Philly]

Women’s cancers: curable for the rich, often a death sentence for the poor [The Conversation]

Sellafield, radiation and childhood cancer – shedding light on cancer clusters near nuclear sites [Cancer Research UK]

Cancer deaths among women to rise 60% by 2030, new reports warn [The Guardian]

Cheap cancer measures could save hundreds of thousands of lives in poor countries [Reuters]

6.10.1 Politiques (USA)

Fearing Democratic tidal wave, the drug industry is pouring money into GOP coffers [STAT]

6.11 Patients

My cancer diary: ‘There’s a new drug, but the NHS won’t pay. Private cost? £15,624 a month!’ [The Guardian]

‘Going Flat’ After Breast Cancer (NY Times]

6.3 Associations/Fondations

Giving Special Section: Medical Charities Once Advised on Coping With a Disease. Now They Try to Cure It. [NY Times]

6.4 Médico-éco

Financial toxicity: a potentially devastating side effect of treating cancer [STAT]

Costs keep women from taking drugs to prevent cancer’s return [Reuters]

6.6 Publications

Publisher Retracts Dozens of Studies [The Scientist]

What should you do if a paper you’ve cited is later retracted? [Retraction Watch]

6.8 Communication

Early report card on quality of FDA news releases: C at best [HealthNewsReview]

6.9 Controverses

J&J Loses Third Trial Over Cancer Link to Talcum Powder [Bloomberg]